OR WAIT null SECS
Growth and Advancements in Fill/Finish
Employing novel technologies and more patient-centric approaches
Delving into Biopharmaceutical Development and Manufacturing
Quality Considerations in Changing Excipient Providers
February 15, 2024
A look at the newest innovations offers a deeper understanding of affinity ligands and their role in the future of downstream processing.
BioVaxys has acquired the full portfolio of discovery, preclinical, and clinical development-stage assets of the former IMV.
This article looks at the relationship between a CDMO quality organization and the client.
What do you need to ask during the vetting and selection process to ensure your clinical or commercial program won’t be derailed by a quality-related problem?
The company’s Itasca, Ill., facility will offer chemistry, manufacturing, and controls analytical testing support.
February 12, 2024
Under the new partnership, Samsung Biologics will develop and manufacture an antibody for a LegoChem Biosciences ADC candidate.
The agency’s safety committee stressed the risk of potential adverse reactions involved with taking Paxlovid (nirmatrelvir, ritonavir) in combination with certain immunosuppressants.
February 09, 2024
The three non-commercial developers of ATMPs will benefit from enhanced support from the agency.
February 08, 2024
Through a €2.7 billion (US$2.9 billion) acquisition of MorphoSys, Novartis will get pelabresib, a late-stage drug candidate in development for cancer treatment.
February 07, 2024
The guidance discusses how to timely notify the agency of changes in production of APIs and finished products.